Exten Industries (fka BB: EXTI)

[Patricia_1]

Excerpts and opinions Part 2

"""The most convincing and reassuring statement in the entire 10Q listed today is the last paragraph. This is where they bring up the future agreement with Xenotech without mentioning their name. Of course, they made the agreement. They were most likely close to closing the deal when this was originally released. They realized that by closing this deal it would make them cash flow positive. In essence, by signing the deal, they guaranteed they would make it:

The Company is also discussing agreements with distribution partners. Such an agreement will involve a cash investment by the partner to MultiCell to obtain the rights to distribute our cells. There are a number of companies that currently sell products similar to the cell products that we have. These companies have the sales and distribution forces in place and could add our product maximizing the strengths of both companies. Our goal is to find partners that can help us in all segments of the markets. These could include for example, pharmaceutical companies, contract toxicology labs, and industrial labs. The cash investments would be followed by sales and royalty revenues to maintain positive cash flow for the Company.

If there is any doubt that this company wasn't going to make it...That doubt should be replaced with confidence.
This company may not have cash flow or even strong numbers with the annual ending this month. However, this will be the last year they will report negative numbers. They made the deal that made the company. There is nowhere to go but up from here. It is a perfect time to invest in this company. They set out to get a contract to make them positive, they did it and the results have not yet hit the
10Q but they will shortly.""" (arubaviax10 RB 15486)

"""Since 1st $1,500,000 was already received, the company is guaranteed a minimum of another $16,500,000 over the next 7 years. What don't you understand?

$16,500,000/84 months=$196,428 a month to Exten over the next 7 years. I know this may not seem like alot but it is a GUARANTEED influx of cash every month.""" (ccc343 RB 15491)

"We have received orders from three major pharmaceutical companies where efficacy evaluation is currently taking place. Even with the proven results of the Pfizer research study that was concluded in November of 2002, given the major procedural change that a cell line would involve, each pharmaceutical company must satisfy itself that our cells will meet their needs."

From 10QSB "Human liver cells are the most bio-chemically complex cells in the body. One of their important functions relates to the production of proteins that are used by the body to perform vital functions such as blood clotting. MultiCell has developed culture conditions wherein cells are creating a number of these proteins."

"We are currently in discussion with numerous pharmaceutical companies about research agreements or direct purchase of our cells. Three major pharmaceutical companies are currently evaluating the cells for use in their research facilities."

By: ccc343
17 Nov 2003, 07:31 PM EST
Msg. 15516 of 15569
Jump to msg. #
aruba...It was mentioned in a post along the way that major pharma procedural changes don't happen overnight. If our cells do become the "gold standard" it will take some time for pharma's to adopt new policy and procedures on how to implement the new technology. The excerpt below proves this statement to be true...I am smiling..


Even with the proven results of the Pfizer research study that was concluded in November of 2002, given the major procedural change that a cell line would involve, each pharmaceutical company must satisfy itself that our cells will meet their needs.

By: arubaviax10
17 Nov 2003, 07:41 PM EST
Msg. 15520 of 15569
Jump to msg. #
Roche has verified however there has been no deal announced with Roche. I would expect Roche (euro pharma) and an ASIAN pharma to announce deals soon.

(Roche http://home.comcast.net/~dcmack2/Roche.html )

By: maxleverage
17 Nov 2003, 08:14 PM EST
Msg. 15525 of 15569
Jump to msg. #
"Our media, which is our own formulation and has been kept as a trade secret, is exclusively used with our immortalized cells to achieve the functions associated with the cells. The cells do not function at the same level without the media."
------------------------------------------------------------

Exten, with that statement has announced another market. In fact Roche's presentation evaluated Multicell's "MultiFunction Enhancing Medium MFE" and compared it with "HMM™ - Hepatocyte Maintenance Medium."

http://www.cambrex.com/CatNav.asp oid=530&prodoid=Hepmainmedia
--------------------------------------------------------------

By: ccc343
17 Nov 2003, 08:27 PM EST
Msg. 15528 of 15569
(This msg. is a reply to 15526 by tradenride.)
Jump to msg. #
trade...FDA approval for what?? Sybiol, yes.

Cell lines for testing liver toxicity in new drugs..NO

Only when a product will come in contact with HUMAN subjects is FDA approval needed.
-------------------------------------------------------------
By: stillpursuing
17 Nov 2003, 10:36 PM EST
Msg. 15548 of 15570
(This msg. is a reply to 15539 by tieffelhunden.)
Jump to msg. #
tieffelhunden....I am an Industrial Sales Specialist for my company. I can tell you that the average sales cycle once begun in the funnel,can take months on average to complete.

From inception until an agreement and contract are finalized the negotiation and then agreement into the close take time.

I can assure that my average sale of $65k - $100k per client closed is no where near that of the average sale for EXTI. This explains the time to close for their particular industry.

Secondly, the price structure per deal for EXTI will most certainly contain set pricing. Meaning,they will not be offering a different pricing structure for different clients. The cell plates will most likely be priced according to length of the contract and the quantities involved.If Pfizer and Roche both sign 3 year deals for the same amount of cell plates,I would assume both contracts would provide identical pricing. The only difference my be customization of the cell lines for specific testing needs.

EXTI will not want to alienate potential customers by offering special pricing to a few.

I've read the last 3 10Q's at least twice each this evening and there are MANY distinct differences in this last one from the previous two. EXTI will be closing deals IMO over the next several Q's. The product is viable and unique. One of a kind breakthrough technology that will change the way pharmas screen new drugs during testing.

Remeber the previous PR."Revolutionary breaktrough technology"."Significant worldwide interest". As soon as these "major" pharmas validate these cells for themselves, watchout above.

EXTI is going to be THE MAJOR player in the test kit niche.

JMO.
-------------------------------------------------------------

Sorry if I have duplicated some of the information as I am doing copying and pasting for all the research on this.

Do your own DD to make ANY decisions to purchase any stock.